TNF and rheumatoid arthritis: By neutralizing the endogenous TNF-α, some anti-TNF-α monoclonal antibodies (mAb, such as etanercept and infliximab) and soluble TNF-α receptor have been successfully used to attenuate pain and symptoms in patients suffering from CD and RA [5–7].